This combination may include PD-1/PD-L1 antibodies to be used along with other immune checkpoint inhibitors (e.g., CTLA-4 antibodies), neoantigen tumor vaccines, antiviral drugs, anti-microbiome modulators, chemotherapy, and radiation therapy [67]. This evidence concerns the gene PDCD1 and neoplasm.